Ubco company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Series B | Alive

Total Raised


Last Raised

$10M | 8 mos ago



About Ubco

Ubco is an electric bike manufacturer. Its flagship product Ubco 2x2 is a Dual Electric Drive Utility Bike, which is a lightweight, near-connected utility vehicle that embraces portable energy. Featuring near silent motors, the Ubco 2x2 can roam for over a 100km, and is fully recharged in six hours for the cost of approx. 88 cents worth of electricity.

Ubco Headquarter Location

20B Newton Street

Mount Maunganui, 3116,

New Zealand

+64 0800 822 6292

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ubco

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ubco is included in 2 Expert Collections, including Bike & Scooter Tech.


Bike & Scooter Tech

352 items

We define bike and scooter technology startups as companies working on shared vehicle networks, vehicle design, and charging infrastructure for bicycles, scooters, mopeds, and other compact vehicles for one to two passengers.


Auto & Mobility Tech

1,073 items

Companies developing battery electric vehicles (BEVs) and fuel cell vehicles (FCEVs) as well as companies working on improvements to battery design, building out charging infrastructure, and launching EV sharing services to help accelerate adoption.

Ubco Patents

Ubco has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics





Application Date


Grant Date



Related Topics



Latest Ubco News

UBCO researchers explore therapeutic uses of ketamine

Mar 18, 2022

UBCO researchers explore therapeutic uses of ketamine Now, ketamine is getting a closer look. Researchers from UBC Okanagan and the University of Exeter have identified ketamine as a potentially powerful tool in the fight against mental illness. In a recent study published in the British Journal of Psychiatry, the research team found ketamine to have significant anti-depressant and anti-suicidal effects. They also found evidence that suggests its benefits don’t stop there. Led by Psychology Professor Dr. Zach Walsh and doctoral student Joey Rootman—both based in the Irving K. Barber Faculty of Arts and Social Sciences—the research team arrived at this conclusion after analyzing more than 150 worldwide studies on the effects of sub-anesthetic ketamine doses for the treatment of mental illness. The study was co-led by Professor Celia Morgan and doctoral student Merve Mollaahmetoglu from the University of Exeter in the United Kingdom. “We found strong evidence that indicates ketamine provides rapid and robust anti-depressant and anti-suicidal effects, but the effects were relatively short-lived,” explains Rootman. “However, repeated dosing appeared to have the potential to increase the duration of positive effects.” Beyond these results, the study provides evidence that suggests ketamine may be helpful in the treatment of other disorders, including eating disorders, problematic substance use, post-traumatic stress and anxiety—though the evidence in these areas is scarce. “What our research provides is an up-to-date overview and synthesis of where the knowledge on ketamine is at right now,” explains Rootman. “Our results signal that ketamine may indeed have a broader spectrum of potential applications in psychiatric treatment—and that tells us that more investigation is needed.” This study serves as a foundation for fellow researchers looking to design ketamine-related projects and offers valuable data for clinicians considering using ketamine with their patients. The results also help to satisfy the public’s appetite for information on innovative and emerging psychiatric treatments, says Dr. Walsh, explaining the review provides a relatively compact document with evidence regarding which ketamine treatments may be helpful for diverse diagnoses. “As many as one in five Canadians will experience a mental illness this year, and the reality is that existing treatments don’t work for everyone,” he says. “As a result, many Canadians are curious about new approaches to help with these serious conditions.” Overall, while Dr. Walsh acknowledges research into other treatment areas is just beginning, he finds the preliminary evidence encouraging. “We need a lot more information on how these interventions could work—for example, administering the drug is only a part of treatment. We need to figure out what amount and type of psychotherapy would best compliment the drug intervention to really maximize potential benefits,” he explains. “With that being said, it is a truly exciting time for ketamine research. If it can deliver the relief that early evidence suggests it can, this could be among the most significant developments in mental health treatment in decades.”

Ubco Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ubco Rank

  • When was Ubco founded?

    Ubco was founded in 2015.

  • Where is Ubco's headquarters?

    Ubco's headquarters is located at 20B Newton Street, Mount Maunganui.

  • What is Ubco's latest funding round?

    Ubco's latest funding round is Series B.

  • How much did Ubco raise?

    Ubco raised a total of $20.84M.

  • Who are the investors of Ubco?

    Investors of Ubco include Enterprise Angels, Seven Peaks Ventures, TPK Holding, Nuance Capital, GD10 Ventures and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.